Antidepressants Explained: SSRIs, SNRIs, and What to Actually Expect

Patients often hear that antidepressants “fix a chemical imbalance.” A 2022 umbrella review challenged that simple serotonin story—but media headlines sometimes implied the drugs do not work. Both shortcuts miss the point: mechanism and effectiveness are related but not the same question.

How SSRIs and SNRIs are usually explained

SSRIs (selective serotonin reuptake inhibitors)—such as fluoxetine, sertraline, and escitalopram—block reuptake of serotonin in the synapse, increasing availability for signaling. SNRIs (serotonin–norepinephrine reuptake inhibitors)—such as venlafaxine and duloxetine—affect serotonin and norepinephrine pathways.

This is still the standard patient-facing explanation on many health sites (including NHS-style materials): understandable shorthand about where the molecules act, not a full theory of depression.

What 2022 research actually found

Moncrieff, Cooper, Stockmann, Amendola, Hengartner, and Horowitz published an umbrella review in Molecular Psychiatry (2022), synthesizing meta-analyses and systematic reviews on serotonin and depression. They concluded there is no consistent evidence supporting the hypothesis that depression is caused by lower serotonin activity or concentration, and no clear association between serotonin measures and depression in the literature they reviewed.

That finding targeted a specific causal story, not every possible biological contribution to mood disorders.

Effectiveness is a separate question

Psychiatrists responding to the review—including APA voices such as Dr. Jonathan Alpert, quoted in public discussions—emphasized a distinction: whether antidepressants show benefit in randomized trials is not answered by serotonin-level studies alone.

Oxford psychopharmacologist Phil Cowen and others noted that modern theories of antidepressant action do not depend on correcting a pre-existing “chemical imbalance” patients were never formally tested for. The imbalance phrase was communication shorthand; clinical adoption rested on controlled outcome data, tolerability, and guideline synthesis—not a single lab test.

Reading Moncrieff et al. as “pills are pointless” is a harmful misreading of the findings.

A more current picture of mechanisms

Responses in the literature (including commentaries such as “Serotonin and depression: a riposte to Moncrieff et al.”) point to multiple systems: serotonin, norepinephrine, dopamine, stress-axis regulation, inflammatory pathways, and neuroplasticity (how synapses and networks adapt over weeks of treatment).

SNRIs are often chosen when low energy, poor concentration, or physical fatigue dominate—symptoms linked to norepinephrine/dopamine circuits as well as serotonin. SSRIs remain first-line for many depression and anxiety presentations; individual response and side effects still drive selection with your prescriber.

Antidepressants are not “happy pills.” They often reduce symptom floor so sleep, therapy homework, and daily function become possible—see depression awareness and therapy vs medication for how combined care fits moderate-to-severe episodes.

Practical expectations when starting medication

Clinical guidance across SSRI and SNRI classes suggests:

• Onset — some sleep or appetite effects may appear in 1–2 weeks; full therapeutic benefit often takes 4–8 weeks (sometimes longer). Stopping at day ten because mood is unchanged usually ends the trial too early.
• Initial vs later side effects — nausea, jitteriness, or sleep shifts may fade; sexual side effects or emotional blunting may persist and warrant dose or agent changes.
• Anxiety — some people feel temporarily more anxious when starting SSRIs; report this rather than silently quitting.

Track mood with PHQ-9 and worry with GAD-7 on One Mental Hub or via PHQ-9 and GAD-7 landing pages. Track your mental health over time gives prescribers trend lines, not one-off guesses.

Stopping or switching requires medical guidance

Moncrieff’s team and standard psychiatric practice agree: do not stop abruptly after long use. Discontinuation symptoms (“brain zaps,” dizziness, irritability, flu-like feelings) are real. Taper plans belong with the prescriber who knows your history, other medications, and relapse risk.

If therapy vs medication led you to try pills, this article covers what happens once you start; that companion piece covers whether to start and how to combine with psychotherapy.

Never mix prescription antidepressants with unsupervised “natural” substitutes—see interaction risks in existing content on herb–drug overlap.

Side effects, monitoring, and special populations

Common discussions at follow-up visits include sleep changes, weight appetite shifts, sexual function, and emotional blunting. Young adults starting SSRIs warrant close monitoring per regulatory guidance on activation and suicidal ideation in some populations. Pregnancy, breastfeeding, and medical comorbidities (cardiac, bipolar spectrum history) change risk–benefit calculus—share full history with your prescriber, including supplements and recreational drugs.

Bipolar disorder misdiagnosed as depression is one reason clinicians review mood timeline before starting antidepressants alone; manic history matters even if current episode feels purely “low.”

How screening fits prescriber visits

Bring four to eight weeks of PHQ-9/GAD-7 readings. Patterns guide decisions:

• Scores falling with therapy alone → medication may stay optional
• Scores high despite therapy → discuss dose trials or augmentation
• Safety item endorsed on PHQ-9 → urgent clinical response, not email-only adjustment

Functional impairment matters too: if work or relationships collapse, discuss WSAS results or WSAS screening alongside mood scores.

When to seek professional help urgently

Seek emergency care for suicidal intent, mania, psychosis, or severe medication reactions (allergic symptoms, sudden agitation). Contact your prescriber promptly for worsening mood in the first weeks, pregnancy planning, or any thought of stopping without a taper.

Take the PHQ-9 screening online

Explore what PHQ-9 measures, how scoring works, and when to seek help on our PHQ-9 screening page. When you are ready, start a confidential assessment on One Mental Hub.

Related guides

• Therapy vs medication
• Depression awareness
• PHQ-9 depression screening guide
• GAD-7 anxiety screening explained
• How to find a therapist
• First therapy session: what to expect
• Track your mental health over time

This article is educational and does not replace medical advice, diagnosis, or treatment. Do not start, stop, or change antidepressants without a qualified prescriber. If you are in crisis, contact emergency services or a crisis line in your country. Review our medical disclaimer.